帕博利珠单抗联合恩扎卢胺对比安慰剂联合恩扎卢胺治疗化疗初治转移性去势抵抗性前列腺癌:随机双盲III期KEYNOTE-641研究
KEYNOTE-641研究纳入1244例化疗初治转移性去势抵抗性前列腺癌患者,随机接受帕博利珠单抗或安慰剂联合恩扎卢胺治疗。主要终点总生存期(中位24.7 vs 27.3个月,HR 1.04,95%CI 0.88-1.22,P=0.66)和影像学无进展生存期(中位10.4 vs 9.0个月,HR 0.98,95%CI 0.84-1.14,P=0.41)均未达到。联合组≥3级治疗相关不良事件发生率更高(31.2% vs 10.8%),研究因总生存期无效边界交叉而终止。
要点
- 帕博利珠单抗联合恩扎卢胺未改善化疗初治mCRPC的总生存期和影像学无进展生存期。
- 联合组≥3级治疗相关不良事件发生率为31.2%,高于安慰剂组的10.8%。
- 总生存期预设无效边界被跨越,研究停止。
核心结论
- 在化疗初治转移性去势抵抗性前列腺癌患者中,恩扎卢胺基础上加用帕博利珠单抗未改善疗效结局,且联合方案观察到额外毒性。
研究设计与样本
- 随机、双盲、III期KEYNOTE-641研究,纳入1244例化疗初治转移性去势抵抗性前列腺癌男性患者,按1:1随机分配至帕博利珠单抗联合恩扎卢胺组(n=621)或安慰剂联合恩扎卢胺组(n=623)。
- 帕博利珠单抗200 mg或安慰剂静脉给药每3周一次,最多35个周期,联合恩扎卢胺160 mg口服每日一次。
- 双主要终点为总生存期和基于PCWG改良RECIST v1.1由盲态独立中心评估的影像学无进展生存期,安全性为次要终点。
主要发现
- 截至2022年12月12日数据截止,中位随访27.6个月(范围6.1-39.8个月)。
- 总生存期中位帕博利珠单抗联合恩扎卢胺组24.7个月 vs 安慰剂联合恩扎卢胺组27.3个月,HR 1.04,95%CI 0.88-1.22,P=0.66,未达到主要终点。
- 影像学无进展生存期中位帕博利珠单抗联合恩扎卢胺组10.4个月 vs 安慰剂联合恩扎卢胺组9.0个月,HR 0.98,95%CI 0.84-1.14,P=0.41,未达到主要终点。
- 总生存期预设无效边界被跨越,研究停止。
- ≥3级治疗相关不良事件在帕博利珠单抗联合恩扎卢胺组(至少接受一剂)615例中发生192例(31.2%),在安慰剂联合恩扎卢胺组(至少接受一剂)620例中发生67例(10.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Established first- and second-line standard-of-care treatment options (abiraterone, enzalutamide, taxane chemotherapy) are available for patients with metastatic castration-resistant prostate cancer (mCRPC), but almost all patients experience subsequent disease progression. The randomized, double-blind, phase III KEYNOTE-641 study evaluated pembrolizumab plus enzalutamide versus placebo plus enzalutamide in participants with chemotherapy-naive mCRPC. PATIENTS AND METHODS: Eligible participants were males aged ≥18 years with confirmed mCRPC and no prior chemotherapy except docetaxel in the hormone-sensitive setting. Prior abiraterone treatment was permitted. Participants were randomly assigned 1:1 to receive pembrolizumab 200 mg or placebo intravenously once every 3 weeks for ≤35 cycles plus enzalutamide 160 mg orally daily. Dual primary end points were overall survival (OS) and radiographic progression-free survival (rPFS) per Prostate Cancer Clinical Trials Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review. Safety was a secondary end point. RESULTS: Between 21 August 2019, and 10 June 2022, 1244 participants were randomly assigned to pembrolizumab plus enzalutamide (n = 621) or placebo plus enzalutamide (n = 623). At the data cut-off date (12 December 2022), median follow-up was 27.6 months (range, 6.1-39.8 months). Primary end points of OS [median, 24.7 versus 27.3 months; hazard ratio (HR) 1.04, 95% confidence interval (CI) 0.88-1.22, P = 0.66] and rPFS (median, 10.4 versus 9.0 months; HR 0.98, 95% CI 0.84-1.14, P = 0.41) with pembrolizumab plus enzalutamide versus placebo plus enzalutamide were not met. The prespecified boundary for futility for OS was crossed, and the study was stopped. Grade ≥3 treatment-related adverse events occurred in 192 of 615 participants (31.2%) with one or more doses of pembrolizumab plus enzalutamide and in 67 of 620 participants (10.8%) with one or more doses of placebo plus enzalutamide. Seventy-one (11.5%) and 21 (3.4%) participants, respectively, discontinued study treatment due to treatment-related adverse events. CONCLUSION: Adding pembrolizumab to enzalutamide did not improve efficacy outcomes for participants with chemotherapy-naive mCRPC. Additional toxicity was observed with the combination regimen.
引用
- Graff JN, Burotto M, Fong PC, et al. Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. Ann Oncol. 2025. PMID: 40383193. doi:10.1016/j.annonc.2025.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。